Esophageal Neoplasms
170
27
30
70
Key Insights
Highlights
Success Rate
76% trial completion
Published Results
15 trials with published results (9%)
Research Maturity
70 completed trials (41% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.9%
22 terminated out of 170 trials
76.1%
-10.5% vs benchmark
11%
19 trials in Phase 3/4
21%
15 of 70 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 70 completed trials
Clinical Trials (170)
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Spatial MSC Index for Predicting Anti-PD-1 Efficacy in Esophageal Cancer
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
Comparison of 0.4% Hyaluronic Acid Solution Versus Hydroxyethylamide Solution in Submucosal Endoscopic Resections
Comparative Study Between (FC-SEMS) and (PC-SEMS) in the Palliation of Dysphagia Due to Malignant Neoplasm of Esophagus.
Phase I Platinum Based Chemotherapy Plus Indomethacin
Effects of Preoperative Enteral Immunonutrition for Esophageal Cancer Patients Given Neoadjuvant Chemoradiotherapy
Rehabilitation and Recovery for Persons With Esophageal or Gastric Cancer
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Luso-Cor Stent Compared to Other Endoscopic Techniques for Management of Fistulas and Anastomotic Dehiscences(ES-LCCE-UDFM)
A Clinical Study on the Effect of Massaging Tian Tu Acupoint on Coughing After Esophageal Surgery
Mayo Clinic Upper Digestive Disease Survey
Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer
PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer
Effects of Bright-light Exposure Combined With Specific Exercise Training (BEST) Program in Patients With Cancer
Esophageal Cancer Multimodal Prehabilitation Study
Assessment of Response to nCRT for GEJ Cancer Using a Fully Integrated PET/MRI
Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer